Knight Therapeutics Inc. (TSX:GUD)
Canada
· Delayed Price · Currency is CAD 7.38
-0.15 (-1.99%)
Apr 28, 2026, 4:00 PM EST
Knight Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 450.09 | 371.3 | 328.2 | 293.56 | 243.48 | Upgrade
|
| Revenue Growth (YoY) | 21.22% | 13.13% | 11.80% | 20.57% | 22.03% | Upgrade
|
| Cost of Revenue | 249.86 | 196.9 | 175.55 | 155.5 | 128.07 | Upgrade
|
| Gross Profit | 200.23 | 174.41 | 152.65 | 138.06 | 115.41 | Upgrade
|
| Selling, General & Admin | 124.11 | 99.35 | 83.69 | 88.62 | 74.38 | Upgrade
|
| Research & Development | 28.98 | 23.3 | 17.55 | 14.76 | 12.69 | Upgrade
|
| Amortization of Goodwill & Intangibles | 49.49 | 44.36 | 45.04 | 51.74 | 41.18 | Upgrade
|
| Operating Expenses | 202.58 | 167.01 | 146.28 | 155.12 | 128.24 | Upgrade
|
| Operating Income | -2.35 | 7.4 | 6.37 | -17.06 | -12.83 | Upgrade
|
| Interest Expense | -10.42 | -9.22 | -12.49 | -6.6 | -3.62 | Upgrade
|
| Interest & Investment Income | 6.21 | 10.41 | 12.58 | 10.63 | 7.38 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.86 | -4.19 | -15.17 | 7.44 | -3.74 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.27 | 0.23 | 12.3 | -22.68 | 19.07 | Upgrade
|
| EBT Excluding Unusual Items | -6.98 | 4.62 | 3.58 | -28.27 | 6.27 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2.34 | -11.79 | -19.62 | - | - | Upgrade
|
| Asset Writedown | - | - | -9.26 | -23.98 | - | Upgrade
|
| Other Unusual Items | 2.62 | 9.23 | 3.3 | 8.29 | 0.42 | Upgrade
|
| Pretax Income | -6.7 | 2.05 | -21.99 | -43.96 | 6.69 | Upgrade
|
| Income Tax Expense | -1.33 | -2.28 | -5.15 | -14.07 | -8.99 | Upgrade
|
| Earnings From Continuing Operations | -5.37 | 4.33 | -16.84 | -29.89 | 15.68 | Upgrade
|
| Net Income | -5.37 | 4.33 | -16.84 | -29.89 | 15.68 | Upgrade
|
| Net Income to Common | -5.37 | 4.33 | -16.84 | -29.89 | 15.68 | Upgrade
|
| Net Income Growth | - | - | - | - | -62.74% | Upgrade
|
| Shares Outstanding (Basic) | 100 | 101 | 107 | 115 | 124 | Upgrade
|
| Shares Outstanding (Diluted) | 100 | 101 | 107 | 115 | 125 | Upgrade
|
| Shares Change (YoY) | -1.84% | -5.61% | -6.46% | -7.74% | -5.66% | Upgrade
|
| EPS (Basic) | -0.05 | 0.04 | -0.16 | -0.26 | 0.13 | Upgrade
|
| EPS (Diluted) | -0.05 | 0.04 | -0.16 | -0.26 | 0.13 | Upgrade
|
| EPS Growth | - | - | - | - | -60.55% | Upgrade
|
| Free Cash Flow | 67.05 | 33.81 | 34.99 | 42.12 | 40.79 | Upgrade
|
| Free Cash Flow Per Share | 0.67 | 0.33 | 0.33 | 0.37 | 0.33 | Upgrade
|
| Gross Margin | 44.49% | 46.97% | 46.51% | 47.03% | 47.40% | Upgrade
|
| Operating Margin | -0.52% | 1.99% | 1.94% | -5.81% | -5.27% | Upgrade
|
| Profit Margin | -1.19% | 1.17% | -5.13% | -10.18% | 6.44% | Upgrade
|
| Free Cash Flow Margin | 14.90% | 9.11% | 10.66% | 14.35% | 16.75% | Upgrade
|
| EBITDA | 49.4 | 55.96 | 53.26 | 40.98 | 32.46 | Upgrade
|
| EBITDA Margin | 10.98% | 15.07% | 16.23% | 13.96% | 13.33% | Upgrade
|
| D&A For EBITDA | 51.75 | 48.56 | 46.89 | 58.04 | 45.29 | Upgrade
|
| EBIT | -2.35 | 7.4 | 6.37 | -17.06 | -12.83 | Upgrade
|
| EBIT Margin | -0.52% | 1.99% | 1.94% | -5.81% | -5.27% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.